cardiology
Medicines

Enormous rivaroxaban study stopped early for ‘overwhelming efficacy’

The very large COMPASS study has been stopped early for “overwhelming efficacy,” according to a press release issued by Bayer AG and Janssen, manufacturers of rivaroxaban (Xarelto). The phase 3 trial randomized 27,402 patients with coronary artery disease (CAD) and peripheral artery disease (PAD) to receive either rivaroxaban 2.5 mg twice daily in addition to ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic